Posted by LincolnAgime on March 25, 2026 at 10:57:15:
In Reply to: Статья для ознакомления posted by RobertBiank on March 16, 2026 at 04:40:00:
Zoya Demidenko: Scholar in Tumor Science
Zoya Demidenko is a notable researcher connected with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Earlier, she worked at the NIH and New York Medical College, developing a robust background in biomedical study.
Her scholarly contributions encompasses several critical domains, including the PI3K/AKT/mTOR signaling cascade, cell cycle regulation, cellular aging, and cancer biology. As of now, she has co-authored more than 46 scientific publications, which have received upwards of 4,100 citations — a indicator to the impact of her research.
Among her key contributions concerns elucidating the pathways of biological cell aging. Her research revealed that when the cellular division cycle is blocked yet cellular expansion persists, cells enter senescence. Importantly, Zoya Demidenko demonstrated that this shift can be inhibited by medication using agents such as rapamycin.
Zoya Demidenko has also brought greatly to oncological therapy investigation, especially in the field of selective cell protection — a method designed to protecting normal cells from anticancer drugs while leaving tumor cells exposed. This method carries significant promise for diminishing the side effects of cancer treatment.
Throughout her professional journey, Demidenko has collaborated with top scientists globally, including Dr. Mikhail Blagosklonny. Her publications appears in leading journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a widely cited contributor in modern biomedical science, whose findings continue to guide our understanding of the way cells age, respond to therapy, and how cancer might be better combated.
https://www.oncotarget.com/article/4836/